GSK looks to authorized generic version of asthma treatment as Medicaid rebate caps lift next year
GSK is gearing up to discontinue the brand-name version of its asthma medication Flovent, just as the Medicaid rebate cap is ending in January 2024 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
